These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
139 related articles for article (PubMed ID: 17395591)
41. Regulators of complement activity mediate inhibitory mechanisms through a common C3b-binding mode. Forneris F; Wu J; Xue X; Ricklin D; Lin Z; Sfyroera G; Tzekou A; Volokhina E; Granneman JC; Hauhart R; Bertram P; Liszewski MK; Atkinson JP; Lambris JD; Gros P EMBO J; 2016 May; 35(10):1133-49. PubMed ID: 27013439 [TBL] [Abstract][Full Text] [Related]
42. Cooperation between decay-accelerating factor and membrane cofactor protein in protecting cells from autologous complement attack. Brodbeck WG; Mold C; Atkinson JP; Medof ME J Immunol; 2000 Oct; 165(7):3999-4006. PubMed ID: 11034410 [TBL] [Abstract][Full Text] [Related]
43. Structure-function relationships of complement receptor type 1. Krych-Goldberg M; Atkinson JP Immunol Rev; 2001 Apr; 180():112-22. PubMed ID: 11414353 [TBL] [Abstract][Full Text] [Related]
44. Reduced activity of DAF on complement enzymes bound to alternative pathway activators. Similarity with Factor H. Pangburn MK Immunology; 1990 Dec; 71(4):598-600. PubMed ID: 1703989 [TBL] [Abstract][Full Text] [Related]
45. The structure of C2b, a fragment of complement component C2 produced during C3 convertase formation. Krishnan V; Xu Y; Macon K; Volanakis JE; Narayana SV Acta Crystallogr D Biol Crystallogr; 2009 Mar; 65(Pt 3):266-74. PubMed ID: 19237749 [TBL] [Abstract][Full Text] [Related]
46. Murine membrane inhibitor of complement which accelerates decay of human C3 convertase. Kameyoshi Y; Matsushita M; Okada H Immunology; 1989 Dec; 68(4):439-44. PubMed ID: 2481641 [TBL] [Abstract][Full Text] [Related]
47. Induction of the paroxysmal nocturnal hemoglobinuria phenotype in normal human erythrocytes: effects of 2-aminoethylisothiouronium bromide on membrane proteins that regulate complement. Ezzell JL; Wilcox LA; Bernshaw NJ; Parker CJ Blood; 1991 Jun; 77(12):2764-73. PubMed ID: 1710519 [TBL] [Abstract][Full Text] [Related]
48. DAF in diabetic patients is subject to glycation/inactivation at its active site residues. Flückiger R; Cocuzzi E; Nagaraj RH; Shoham M; Kern TS; Medof ME Mol Immunol; 2018 Jan; 93():246-252. PubMed ID: 28886871 [TBL] [Abstract][Full Text] [Related]
49. Molecular engineering of an efficient four-domain DAF-MCP chimera reveals the presence of functional modularity in RCA proteins. Panwar HS; Ojha H; Ghosh P; Barage SH; Raut S; Sahu A Proc Natl Acad Sci U S A; 2019 May; 116(20):9953-9958. PubMed ID: 31036650 [TBL] [Abstract][Full Text] [Related]
50. The crystal structure of a coxsackievirus B3-RD variant and a refined 9-angstrom cryo-electron microscopy reconstruction of the virus complexed with decay-accelerating factor (DAF) provide a new footprint of DAF on the virus surface. Yoder JD; Cifuente JO; Pan J; Bergelson JM; Hafenstein S J Virol; 2012 Dec; 86(23):12571-81. PubMed ID: 22973031 [TBL] [Abstract][Full Text] [Related]
51. Molecular dissection of interactions between components of the alternative pathway of complement and decay accelerating factor (CD55). Harris CL; Abbott RJ; Smith RA; Morgan BP; Lea SM J Biol Chem; 2005 Jan; 280(4):2569-78. PubMed ID: 15536079 [TBL] [Abstract][Full Text] [Related]
52. The influence of membrane components on regulation of alternative pathway activation by decay-accelerating factor. Mold C; Walter EI; Medof ME J Immunol; 1990 Dec; 145(11):3836-41. PubMed ID: 1700997 [TBL] [Abstract][Full Text] [Related]
53. Identification of amino acids in the Dr adhesin required for binding to decay-accelerating factor. Van Loy CP; Sokurenko EV; Samudrala R; Moseley SL Mol Microbiol; 2002 Jul; 45(2):439-52. PubMed ID: 12123455 [TBL] [Abstract][Full Text] [Related]
54. Bee Venom Alleviates Atopic Dermatitis Symptoms through the Upregulation of Decay-Accelerating Factor (DAF/CD55). Kim Y; Lee YW; Kim H; Chung DK Toxins (Basel); 2019 Apr; 11(5):. PubMed ID: 31027358 [TBL] [Abstract][Full Text] [Related]
55. A cluster of positively charged amino acids in the alpha-chain of C4b-binding protein (C4BP) is pivotal for the regulation of the complement system and the interaction with bacteria. Blom AM Scand J Clin Lab Invest Suppl; 2000; 233():37-49. PubMed ID: 11317941 [TBL] [Abstract][Full Text] [Related]
56. Characterization of the echovirus 7 receptor: domains of CD55 critical for virus binding. Clarkson NA; Kaufman R; Lublin DM; Ward T; Pipkin PA; Minor PD; Evans DJ; Almond JW J Virol; 1995 Sep; 69(9):5497-501. PubMed ID: 7543583 [TBL] [Abstract][Full Text] [Related]
57. Additional forms of human decay-accelerating factor (DAF). Seya T; Farries T; Nickells M; Atkinson JP J Immunol; 1987 Aug; 139(4):1260-7. PubMed ID: 2440950 [TBL] [Abstract][Full Text] [Related]
58. CCP1-4 of the C4b-binding protein alpha-chain are required for factor I mediated cleavage of complement factor C3b. Blom AM; Kask L; Dahlbäck B Mol Immunol; 2003 Jan; 39(10):547-56. PubMed ID: 12431388 [TBL] [Abstract][Full Text] [Related]
59. Inhibition of complement activation on the surface of cells after incorporation of decay-accelerating factor (DAF) into their membranes. Medof ME; Kinoshita T; Nussenzweig V J Exp Med; 1984 Nov; 160(5):1558-78. PubMed ID: 6238120 [TBL] [Abstract][Full Text] [Related]
60. Structural characterization of mouse CD97 and study of its specific interaction with the murine decay-accelerating factor (DAF, CD55). Qian YM; Haino M; Kelly K; Song WC Immunology; 1999 Oct; 98(2):303-11. PubMed ID: 10540231 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]